Qunfeng Luo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Qunfeng Luo has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
Juncheng Li
School of Basic Medical Sciences, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi 330006, People's Republic of China
2 shared publicationsShuli Liu
School of Basic Medical Sciences, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi 330006, People's Republic of China
2 shared publicationsYaoguang Hua
School of Basic Medical Sciences, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi 330006, People's Republic of China
2 shared publicationsAmin Guo
School of Basic Medical Sciences, Jiangxi Medical College, Nanchang University
1 shared publicationChunqiu Long
School of Basic Medical Sciences, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi 330006, People's Republic of China
1 shared publication- Dingfa Liang
Medical School of Chinese PLA, Beijing, China; Department of Orthopedics, Chinese PLA General Hospital, Beijing, China; National Clinical Research Centre for Orthopedics, Sports Medicine & Rehabilitation, Beijing, China
1 shared publication
Latest Publications
- Open Access
- 22 September 2025
- Published by Frontiers Media SA in Frontiers in Chemistry
- Vol. 13, 1659507
Reversed phase HPLC analysis of mobocertinib and its impurities and studies on the structure and biological activity of a new degradation product
Background: Mobocertinib, an epidermal growth factor receptor tyrosine kinase inhibitor, is prescribed for the treatment of non-small cell lung cancer characterized by epidermal growth factor receptor exon 20 insertion mutations. The presence of impurities generated during its synthesis or storage may compromise the drug’s efficacy and safety. Therefore, a comprehensive investigation of these impurities and the implementation of rigorous quality control measures are of paramount importance. However, robust analytical methods for the simultaneous and accurate detection of mobocertinib and its related impurities are currently lacking.Methods: This study developed a novel reversed-phase high-performance liquid chromatography method (RP-HPLC) for separating and analysing mobocertinib and its impurities. An Agilent 5HC-C18 column (4.6 mm × 250 mm, 5 μm) was used to separate Mobocertinib and its related substances. The mobile phase composition, gradient elution program, and ultraviolet detection wavelength were optimized. Additionally, a new product (imp-A) was found during the forced degradation test. Its structure was elucidated by RP-HPLC, nuclear magnetic resonance (NMR) and high resolution mass spectrometry (HRMS). The biological activity of imp-A was preliminarily evaluated by methyl thiazolyl tetrazolium (MTT) assay.Results: The RP-HPLC method developed in this study was validated in accordance with ICH guidelines, demonstrating satisfactory specificity, precision, stability, repeatability, accuracy, and robustness. The method exhibited good linearity over the concentration range of 0.1–20 μg mL-1. The limits of detection and quantitation for mobocertinib were determined to be 0.02 μg mL-1 and 0.05 μg mL-1, respectively. The structure of imp-A was successfully characterized, and its formation mechanism was elucidated. Furthermore, imp-A was found to inhibit the growth of various tumor cell lines.Conclusion: The developed RP-HPLC method is suitable for the simultaneous detection of mobocertinib and its impurities, providing significant advantages for process development and quality control. Imp-A, a novel compound, demonstrated promising anticancer activity in vitro. However, further in vivo studies are required to fully assess its therapeutic potential, which may hold promise for clinical applications in cancer treatment.
- 22 September 2025
- Published by Frontiers Media SA in Frontiers in Chemistry
- Vol. 13, 1659507
Open AccessReversed phase HPLC analysis of mobocertinib and its impurities and studies on the structure and biological activity of a new degradation product
Background: Mobocertinib, an epidermal growth factor receptor tyrosine kinase inhibitor, is prescribed for the treatment of non-small cell lung cancer characterized by epidermal growth factor receptor exon 20 insertion mutations. The presence of impurities generated during its synthesis or storage may compromise the drug’s efficacy and safety. Therefore, a comprehensive investigation of these impurities and the implementation of rigorous quality control measures are of paramount importance. However, robust analytical methods for the simultaneous and accurate detection of mobocertinib and its related impurities are currently lacking.Methods: This study developed a novel reversed-phase high-performance liquid chromatography method (RP-HPLC) for separating and analysing mobocertinib and its impurities. An Agilent 5HC-C18 column (4.6 mm × 250 mm, 5 μm) was used to separate Mobocertinib and its related substances. The mobile phase composition, gradient elution program, and ultraviolet detection wavelength were optimized. Additionally, a new product (imp-A) was found during the forced degradation test. Its structure was elucidated by RP-HPLC, nuclear magnetic resonance (NMR) and high resolution mass spectrometry (HRMS). The biological activity of imp-A was preliminarily evaluated by methyl thiazolyl tetrazolium (MTT) assay.Results: The RP-HPLC method developed in this study was validated in accordance with ICH guidelines, demonstrating satisfactory specificity, precision, stability, repeatability, accuracy, and robustness. The method exhibited good linearity over the concentration range of 0.1–20 μg mL-1. The limits of detection and quantitation for mobocertinib were determined to be 0.02 μg mL-1 and 0.05 μg mL-1, respectively. The structure of imp-A was successfully characterized, and its formation mechanism was elucidated. Furthermore, imp-A was found to inhibit the growth of various tumor cell lines.Conclusion: The developed RP-HPLC method is suitable for the simultaneous detection of mobocertinib and its impurities, providing significant advantages for process development and quality control. Imp-A, a novel compound, demonstrated promising anticancer activity in vitro. However, further in vivo studies are required to fully assess its therapeutic potential, which may hold promise for clinical applications in cancer treatment.
- Open Access
- 6 February 2025
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 15 (6) , 4526-4531
Heterobifunctional cross-linker with dinitroimidazole and azide modules for protein and oligonucleotide functionalization
Heterobifunctional cross-linker 1 facilitates preparing various functional agents bearing a dinitroimidazole warhead via the SPAAC reaction and does well in protein and oligonucleotide functionalization.
- 6 February 2025
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 15 (6) , 4526-4531
Open AccessHeterobifunctional cross-linker with dinitroimidazole and azide modules for protein and oligonucleotide functionalization
Heterobifunctional cross-linker 1 facilitates preparing various functional agents bearing a dinitroimidazole warhead via the SPAAC reaction and does well in protein and oligonucleotide functionalization.
- Open Access
- 31 July 2024
- Published by Life Science Alliance, LLC in Life Science Alliance
- Vol. 7 (10) , e202402584
Differential roles of lysosomal cholesterol transporters in the development ofC. elegansNMJs
Cholesterol homeostasis in neurons is critical for synapse formation and maintenance. Neurons with impaired cholesterol uptake undergo progressive synapse loss and eventual degeneration. To investigate the molecular mechanisms of neuronal cholesterol homeostasis and its role during synapse development, we studied motor neurons ofCaenorhabditis elegansbecause these neurons rely on dietary cholesterol. Combining lipidomic analysis, we discovered that NCR-1, a lysosomal cholesterol transporter, promotes cholesterol absorption and synapse development. Loss ofncr-1causes smaller synapses, and low cholesterol exacerbates the deficits. Moreover, NCR-1 deficiency hinders the increase in synapses under high cholesterol. Unexpectedly, NCR-2, the NCR-1 homolog, increases the use of cholesterol and sphingomyelins and impedes synapse formation. NCR-2 deficiency causes an increase in synapses regardless of cholesterol concentration. Inhibiting the degradation or synthesis of sphingomyelins can induce or suppress the synaptic phenotypes inncr-2mutants. Our findings indicate that neuronal cholesterol homeostasis is differentially controlled by two lysosomal cholesterol transporters and highlight the importance of neuronal cholesterol homeostasis in synapse development.
- 31 July 2024
- Published by Life Science Alliance, LLC in Life Science Alliance
- Vol. 7 (10) , e202402584
Open AccessDifferential roles of lysosomal cholesterol transporters in the development ofC. elegansNMJs
Cholesterol homeostasis in neurons is critical for synapse formation and maintenance. Neurons with impaired cholesterol uptake undergo progressive synapse loss and eventual degeneration. To investigate the molecular mechanisms of neuronal cholesterol homeostasis and its role during synapse development, we studied motor neurons ofCaenorhabditis elegansbecause these neurons rely on dietary cholesterol. Combining lipidomic analysis, we discovered that NCR-1, a lysosomal cholesterol transporter, promotes cholesterol absorption and synapse development. Loss ofncr-1causes smaller synapses, and low cholesterol exacerbates the deficits. Moreover, NCR-1 deficiency hinders the increase in synapses under high cholesterol. Unexpectedly, NCR-2, the NCR-1 homolog, increases the use of cholesterol and sphingomyelins and impedes synapse formation. NCR-2 deficiency causes an increase in synapses regardless of cholesterol concentration. Inhibiting the degradation or synthesis of sphingomyelins can induce or suppress the synaptic phenotypes inncr-2mutants. Our findings indicate that neuronal cholesterol homeostasis is differentially controlled by two lysosomal cholesterol transporters and highlight the importance of neuronal cholesterol homeostasis in synapse development.
- 7 December 2023
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 25 (49) , 8792-8796
Heterobifunctional Cross-Linker with Dinitroimidazole and N-Hydroxysuccinimide Ester Motifs for Protein Functionalization and Cysteine–Lysine Peptide Stapling
A heterobifunctional cross-linker with one sulfhydryl-reactive dinitroimidazole end and another amine-reactive N-hydroxysuccinimide (NHS) ester end was designed and synthesized. The two motifs of this cross-linker, dinitroimidazole and NHS ester, proved to react with thiol and amine, respectively, in an orthogonal way. The cross-linker was further applied to construct stapled peptides of different sizes and mono- and dual functionalization (including biotinylation, PEGylation, and fluorescence labeling) of protein.
- 7 December 2023
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 25 (49) , 8792-8796
Heterobifunctional Cross-Linker with Dinitroimidazole and N-Hydroxysuccinimide Ester Motifs for Protein Functionalization and Cysteine–Lysine Peptide Stapling
A heterobifunctional cross-linker with one sulfhydryl-reactive dinitroimidazole end and another amine-reactive N-hydroxysuccinimide (NHS) ester end was designed and synthesized. The two motifs of this cross-linker, dinitroimidazole and NHS ester, proved to react with thiol and amine, respectively, in an orthogonal way. The cross-linker was further applied to construct stapled peptides of different sizes and mono- and dual functionalization (including biotinylation, PEGylation, and fluorescence labeling) of protein.
- Open Access
- 6 September 2022
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 27 (9) , 257
Combination Therapies against COVID-19
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of Coronavirus disease 2019 (COVID-19), which was announced as a pandemic leading to devastating economic and medical burden worldwide. The virus attacks the organ system across the body by binding to its receptor (for example, angiotensin converting enzyme 2) on the surface of the host cell of various organs. The patients present with a variety of pathological symptoms ranging from fever, cough and cytokine storm to acute respiratory distress syndrome (ARDS). Many combination therapies have been developed to combat the disease, via blocking one or more processes of the viral life cycle and/or relieving host complications simultaneously. In this review, the progress of those combination therapies containing at least one small molecule is updated. We believe it’ll provide significant inspiration for further development of treatment strategy against SARS-CoV-2, especially its mutant variants.
- 6 September 2022
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 27 (9) , 257
Open AccessCombination Therapies against COVID-19
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of Coronavirus disease 2019 (COVID-19), which was announced as a pandemic leading to devastating economic and medical burden worldwide. The virus attacks the organ system across the body by binding to its receptor (for example, angiotensin converting enzyme 2) on the surface of the host cell of various organs. The patients present with a variety of pathological symptoms ranging from fever, cough and cytokine storm to acute respiratory distress syndrome (ARDS). Many combination therapies have been developed to combat the disease, via blocking one or more processes of the viral life cycle and/or relieving host complications simultaneously. In this review, the progress of those combination therapies containing at least one small molecule is updated. We believe it’ll provide significant inspiration for further development of treatment strategy against SARS-CoV-2, especially its mutant variants.